Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

95 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth factor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mutant mice.
Burga LN, Hu H, Juvekar A, Tung NM, Troyan SL, Hofstatter EW, Wulf GM. Burga LN, et al. Among authors: wulf gm. Breast Cancer Res. 2011 Mar 11;13(2):R30. doi: 10.1186/bcr2850. Breast Cancer Res. 2011. PMID: 21396117 Free PMC article.
Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer.
Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM. Juvekar A, et al. Among authors: wulf gm. Cancer Discov. 2012 Nov;2(11):1048-63. doi: 10.1158/2159-8290.CD-11-0336. Epub 2012 Aug 22. Cancer Discov. 2012. PMID: 22915751 Free PMC article.
Phosphoinositide 3-kinase inhibitors induce DNA damage through nucleoside depletion.
Juvekar A, Hu H, Yadegarynia S, Lyssiotis CA, Ullas S, Lien EC, Bellinger G, Son J, Hok RC, Seth P, Daly MB, Kim B, Scully R, Asara JM, Cantley LC, Wulf GM. Juvekar A, et al. Among authors: wulf gm. Proc Natl Acad Sci U S A. 2016 Jul 26;113(30):E4338-47. doi: 10.1073/pnas.1522223113. Epub 2016 Jul 8. Proc Natl Acad Sci U S A. 2016. PMID: 27402769 Free PMC article.
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
Xing Y, Lin NU, Maurer MA, Chen H, Mahvash A, Sahin A, Akcakanat A, Li Y, Abramson V, Litton J, Chavez-MacGregor M, Valero V, Piha-Paul SA, Hong D, Do KA, Tarco E, Riall D, Eterovic AK, Wulf GM, Cantley LC, Mills GB, Doyle LA, Winer E, Hortobagyi GN, Gonzalez-Angulo AM, Meric-Bernstam F. Xing Y, et al. Among authors: wulf gm. Breast Cancer Res. 2019 Jul 5;21(1):78. doi: 10.1186/s13058-019-1154-8. Breast Cancer Res. 2019. PMID: 31277699 Free PMC article. Clinical Trial.
The amplifier effect: how Pin1 empowers mutant p53.
Hu H, Wulf GM. Hu H, et al. Among authors: wulf gm. Breast Cancer Res. 2011 Oct 13;13(5):315. doi: 10.1186/bcr2941. Breast Cancer Res. 2011. PMID: 22017796 Free PMC article.
Effect of testosterone therapy on breast tissue composition and mammographic breast density in trans masculine individuals.
Heng YJ, Baker GM, Fein-Zachary VJ, Guzman-Arocho YD, Bret-Mounet VC, Massicott ES, Torous VF, Schnitt SJ, Gitin S, Russo P, Tobias AM, Bartlett RA, Varma G, Kontos D, Yaghjyan L, Irwig MS, Potter JE, Wulf GM. Heng YJ, et al. Among authors: wulf gm. Breast Cancer Res. 2024 Jul 2;26(1):109. doi: 10.1186/s13058-024-01867-w. Breast Cancer Res. 2024. PMID: 38956693 Free PMC article.
95 results